NET PROFIT (x1000 EUR)
EMPLOYEES
Biocell AB
Closing information (x1000 EUR)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
0
|
0
|
0 |
| Financial expenses |
71
|
0
|
180 |
| Earnings before taxes |
-65
|
10
|
107 |
| EBITDA |
-68
|
-65
|
-60 |
| Total assets |
1,215
|
1,295
|
1,399 |
| Current assets |
372
|
730
|
973 |
| Current liabilities |
170
|
174
|
266 |
| Equity capital |
1,045
|
1,121
|
1,133 |
| - share capital |
87
|
90
|
90 |
| Employees (average) |
1
|
0
|
0 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
86.0%
|
86.6%
|
81.0% |
| Turnover per employee | 0 | ||
| Profit as a percentage of turnover | |||
| Return on assets (ROA) |
0.5%
|
0.8%
|
20.5% |
| Current ratio |
218.8%
|
419.5%
|
365.8% |
| Return on equity (ROE) |
-6.2%
|
0.9%
|
9.4% |
| Change turnover |
0
|
0
|
-3,441 |
| Change turnover % | -100% | ||
| Chg. No. of employees |
1
|
0
|
-1 |
| Chg. No. of employees % | -100% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.